Markers of Infection and Resistance in Invasive Fusariosis

Multicenter Study on Invasive Fusariosis : Looking for Markers of Infection and Resistance

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04937751

Acronym

FUSIMIR

Enrollment

150

Registered

2021-06-24

Start date

2023-07-19

Completion date

2028-07-31

Last updated

2024-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fusariosis

Brief summary

In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. The genus Fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin B. The main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis. The secondary objectives are the description of the dosage of galactomannans, beta (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (MIC) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. Finally, the presence of genetic markers will be described according to the groups of MIC values.

Interventions

DIAGNOSTIC_TESTbiomarkers

galactomannan, betaDglucan, resistance markers

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Suspicion of invasive fungal infection involving the performance of a blood culture or a skin biopsy or diagnosis of keratitis involving the taking of a cornea sample * Fungal culture carried out on this sample * Person having been informed of the research and not having opposed the use of their data

Exclusion criteria

* Clinical diagnosis of superficial fusarium wilt (onychomycosis, etc.)

Design outcomes

Primary

Measure	Time frame
proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis	2021-2026

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026